CMS to reimburse for Mitosol

Mobius Therapeutics has received reimbursement approval from the U.S. Center for Medicare and Medicaid Services (CMS) for Mitosol (mitomycin for solution) kit for ophthalmic use for 2014. The product will be reimbursed at 106 percent of the average sales price.

Mitosol, which delivers antifibrotic agents during glaucoma, refractive and corneal surgery, is currently sold for the glaucoma indication but is awaiting U.S. FDA approval for pterygium and refractive indications.